Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Alkermes reported strong earnings by exceeding both revenue and earnings expectations in its latest quarterly release.

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Health-care companies fell after disappointing earnings from one health insurer. Shares of Humana slid after the health-insurance firm warned of falling Medicare Advantage membership, and hinted that ...

We think the strategy to find more effective combination therapies in hematology and build a larger oncology and dermatology portfolio is solid, although we're waiting for key data before assuming the ...

Hearst Television's National Investigative Unit is learning more about a substance, not considered an opioid, being mixed ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund.